ASTA Comments on FDA Request for Information on Gluten Labeling and Cross-Contact in Packaged Foods
In April 2026, ASTA submitted comments in response to the Food and Drug Administration's (FDA) request for information (RFI) on labeling and cross-contact of gluten in packaged foods, which specifically referenced ingredients that can be declared using collective terms, such as spices. ASTA's comments highlight that no spices inherently contain gluten, note that FDA should take a scientific, risk-based approach to unintended gluten presence, and express support for consistency with existing FDA requirements and harmonization with internal standards for gluten labeling.
04/16/2026 at 12:00 am
14
Related Resources
ASTA Comments on Poppy Seed Practices and Safety
On June 16, 2025, ASTA submitted comments in response to the U.S. Food and Drug Administration's (FDA) Request for Information (RFI) on industry practices on the growing, harvesting, processing, and distribution of poppy seeds. The comments outline the typical poppy seed supply chains, as well as the role of pre- and post-harvest processing steps (e.g., microbiological treatment, baking, etc.) in reducing opiate alkaloid levels in poppy seed-based products.
ASTA Comments to FDA on Bioterrorism Act Prior Notice
ASTA issued comments to the Food & Drug Administration (FDA) in May 2004 regarding prior notice of imported food under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002.
